Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma

NACompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

January 19, 2016

Primary Completion Date

December 21, 2018

Study Completion Date

November 12, 2019

Conditions
Adult Nasal Type Extranodal NK/T-Cell LymphomaAdult T-Cell Leukemia/LymphomaAnaplastic Large Cell LymphomaAngioimmunoblastic T-Cell LymphomaB Lymphoblastic Leukemia/LymphomaBlastic Plasmacytoid Dendritic Cell NeoplasmBurkitt LeukemiaCentral Nervous System LymphomaChronic Lymphocytic Leukemia/Small Lymphocytic LymphomaDiffuse Large B-Cell LymphomaEnteropathy-Associated T-Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueGrade 1 Follicular LymphomaGrade 2 Follicular LymphomaGrade 3 Follicular LymphomaHepatosplenic T-Cell LymphomaLymphoplasmacytic LymphomaMantle Cell LymphomaMediastinal (Thymic) Large B-Cell LymphomaMycosis FungoidesNasal Type Extranodal NK/T-Cell LymphomaNodal Marginal Zone LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPost-Transplant Lymphoproliferative DisorderPrimary Cutaneous Anaplastic Large Cell LymphomaPrimary Effusion LymphomaSezary SyndromeSplenic Marginal Zone LymphomaSubcutaneous Panniculitis-Like T-Cell LymphomaSystemic Anaplastic Large Cell LymphomaT Lymphoblastic Leukemia/LymphomaTransformed Recurrent Non-Hodgkin Lymphoma
Interventions
OTHER

Laboratory Biomarker Analysis

Correlative studies

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

DIETARY_SUPPLEMENT

Salvia hispanica Seed

Given PO

Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Mayo Clinic

OTHER

NCT02652715 - Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | Biotech Hunter | Biotech Hunter